respiratori
viral
infect
global
public
health
concern
common
caus
symptomat
diseas
lead
heavi
econom
burden
due
increas
number
sick
day
borchardt
rolston
kim
et
al
addit
respiratori
diseas
one
common
caus
mortal
develop
countri
ferkol
schraufnagel
among
two
lead
caus
respiratori
viru
infect
influenza
b
virus
respiratori
syncyti
viru
rsv
amarel
et
al
heylen
et
al
yip
et
al
case
observ
infant
children
although
elderli
immunocompromis
also
high
risk
get
infect
develop
sever
diseas
jorquera
tripp
influenza
virus
rsv
circul
season
begin
fall
earli
spring
increas
number
avian
influenza
china
includ
highli
pathogen
hp
strain
viru
continu
outbreak
hp
avian
influenza
hpai
virus
novel
variant
season
influenza
virus
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
highlight
seriou
import
need
develop
novel
effect
antivir
therapi
zumla
et
al
intern
societi
influenza
respiratori
viral
diseas
review
articl
focus
therapi
current
develop
treatment
influenza
rsv
merscov
infect
briefli
review
drug
approv
unit
state
feder
drug
administr
fda
drug
clinic
trial
figur
avail
clinic
trial
identifi
includ
briefli
drug
divid
three
group
ion
channel
blocker
neuraminidas
inhibitor
nai
viru
polymeras
inhibitor
amantadin
rimantadin
adamantan
deriv
inhibit
viral
replic
block
proton
conduct
ion
channel
prevent
deliveri
viru
ribonucleoprotein
cytoplasm
schnell
chou
ison
compound
specif
influenza
virus
sinc
protein
influenza
b
virus
structur
differ
wang
et
al
pielak
chou
recent
past
season
surveil
studi
report
high
level
resist
adamantan
among
circul
influenza
influenza
virus
center
diseas
control
prevent
cdc
recommend
compound
antivir
treatment
chemoprophylaxi
current
circul
influenza
virus
center
diseas
control
prevent
develop
nai
start
earli
deriv
acid
pales
et
al
although
first
nai
approv
use
human
chaudhuri
et
al
nai
bind
neuraminidas
viru
prevent
cleavag
thu
inhibit
releas
new
viru
particl
ison
nai
current
approv
fda
includ
oseltamivir
zanamivir
peramivir
oseltamivir
acid
prodrug
indic
oral
administr
gastrointestin
tract
produg
rapidli
cleav
activ
metabolit
oseltamivir
carboxyl
kim
et
al
due
poor
oral
bioavail
zanamivir
approv
inhal
deliveri
intraven
administr
avail
compassion
use
ison
shaw
peramivir
also
poor
oral
bioavail
therefor
approv
intraven
administr
drug
reach
high
concentr
plasma
respiratori
tissu
approv
singledos
infus
one
inherit
problem
drug
order
effect
treatment
start
within
h
postexposur
antivir
resist
oseltamivir
zanamivir
peramivir
low
current
circul
influenza
viru
strain
although
chang
sever
cluster
oseltamivir
resist
detect
japan
australia
china
takashita
et
al
alam
et
al
koszalka
et
al
also
known
baloxavir
marboxil
prodrug
hydrolyz
vivo
activ
form
select
inhibit
capdepend
endonucleas
prevent
initi
mrna
synthesi
influenza
viru
takashita
et
al
potent
small
molecul
show
activ
sever
influenza
virus
includ
oseltamivirresist
virus
well
b
virus
noshi
et
al
preclin
studi
demonstr
treat
mice
infect
influenza
viru
protect
clinic
sign
mortal
even
delay
treatment
approach
treatment
start
day
postinfect
furthermor
subtherapeut
dose
baloxavir
combin
oseltamivir
also
protect
mice
infect
mortal
fukao
et
al
addit
studi
mice
infect
avian
influenza
virus
also
demonstr
protect
oral
administr
baloxavir
uehara
et
al
clinic
studi
aim
compar
efficaci
baloxavir
placebo
oseltamivir
healthi
patient
infect
influenza
demonstr
drug
well
toler
associ
signific
reduct
viral
load
compar
oseltamivir
group
time
allevi
symptom
similar
oseltamivir
current
undergo
clinic
program
drug
includ
phase
clinic
trial
determin
safeti
pharmacokinet
efficaci
healthi
pediatr
particip
age
less
year
pediatr
patient
influenzalik
symptom
studi
assess
efficaci
safeti
baloxavir
combin
standardofcar
neuraminidas
inhibitor
hospit
particip
sever
influenza
studi
current
recruit
expect
conclud
spring
japan
baloxavir
approv
treatment
adult
infant
patient
infect
influenza
us
drug
approv
fda
treatment
acut
uncompl
influenza
peopl
age
year
older
food
drug
administr
emerg
resist
variant
polymeras
inhibitor
observ
confer
mutat
pa
polymeras
jone
et
al
studi
novel
mutat
confer
resist
also
observ
mutat
encount
clinic
trial
baloxavir
hayden
et
al
given
inherit
limit
current
approv
compound
potenti
risk
aris
antivir
resist
still
urgent
need
develop
new
antiinfluenza
drug
novel
drug
ideal
follow
characterist
effect
deliv
late
infect
low
propens
develop
antivir
resist
broad
activ
influenza
b
improv
effect
compar
standard
care
easili
administ
uncompl
well
complic
case
influenza
koszalka
et
al
shaw
next
summar
advanc
phase
clinic
trial
promis
drug
candid
direct
highli
conserv
helic
region
membraneproxim
stalk
hemagglutinin
vitro
studi
class
mab
demonstr
neutral
activ
across
broad
spectrum
influenza
subtyp
protect
mice
lethal
dose
virus
koudstaal
et
al
challeng
studi
success
demonstr
therapeut
prophylact
efficaci
ferret
model
lethal
dose
viru
friesen
et
al
clinic
trial
phase
aim
determin
reduc
flu
diseas
peopl
treat
drug
versu
placebo
conclud
result
still
avail
target
immunosubdomin
rel
conserv
membraneproxim
stalk
region
hemagglutinin
mab
activ
group
influenza
virus
shown
neutral
activ
subtyp
vitro
vivo
ekiert
et
al
phase
trial
evalu
protect
efficaci
safeti
influenza
challeng
model
complet
unfortun
recent
studi
show
target
region
ha
stalk
prone
escap
therefor
escap
mutant
like
aris
tharakaraman
et
al
product
contain
two
distinct
complementari
mab
shown
broad
efficaci
vitro
vivo
differ
group
group
influenza
virus
phase
clinic
trial
conduct
evalu
efficaci
safeti
influenza
challeng
model
studi
conclud
juli
howev
result
report
current
recruit
phase
clinic
trial
aim
evalu
efficaci
safeti
mab
combo
comparison
placebo
subject
acut
uncompl
influenza
infect
potent
broadli
neutral
investig
human
mab
target
highli
conserv
stalk
region
ha
protein
report
effect
neutral
known
influenza
ha
subtyp
kallewaard
et
al
preclin
studi
anim
model
shown
efficaci
protect
influenza
viru
lethal
challeng
use
alon
combin
oseltamivir
paul
et
al
phase
studi
evalu
safeti
adult
acut
uncompl
influenza
recent
conclud
result
demonstr
accept
safeti
profil
group
patient
receiv
fast
track
design
fda
allow
drug
expedit
develop
review
ali
et
al
human
monoclon
antibodi
contain
vh
heavi
chain
pair
light
chain
mcbride
et
al
target
highli
conserv
epitop
stalk
region
ha
capabl
neutral
test
season
human
influenza
strain
nakamura
et
al
two
mechan
action
describ
mab
one
bind
ha
avid
viru
infect
two
antibodydepend
cellmedi
cytotox
increas
kill
infect
cell
mcbride
et
al
preclin
studi
demonstr
efficaci
mous
model
divers
group
influenza
virus
includ
group
group
strain
even
administ
h
postinfect
addit
synerg
observ
administ
oseltamivir
h
postinfect
final
studi
ferret
demonstr
protect
hpai
viru
challeng
nakamura
et
al
clinic
trial
conduct
evalu
safeti
pharmacokinet
efficaci
alon
combin
oseltamivir
lim
et
al
mcbride
et
al
deng
et
al
result
establish
mab
well
toler
halflif
similar
human
antibodi
day
nonlinear
nasal
pharmacokinet
mcbride
et
al
deng
et
al
furthermor
treatment
significantli
reduc
viral
load
mcbride
et
al
recent
clinic
trial
aim
investig
safeti
clinic
activ
singl
intraven
iv
dose
adult
particip
hospit
sever
influenza
combin
oseltamivir
recent
conclud
result
indic
advantag
primari
clinic
outcom
evalu
compar
standard
care
furthermor
signific
differ
observ
virolog
outcom
evalu
includ
viral
shed
peak
viru
load
novel
nonnucleosid
polymeras
inhibitor
target
subunit
influenza
virus
target
avoid
dock
gtp
cap
structur
thu
prevent
viral
rna
synthesi
clark
et
al
boyd
et
al
earli
activ
pimovidir
cell
cycl
shown
improv
cell
viabil
compar
oseltamivir
byrn
et
al
furthermor
activ
divers
group
influenza
virus
includ
byrn
et
al
preclin
studi
mice
demonstr
protect
lethal
challeng
even
given
day
postinfect
virus
byrn
et
al
studi
also
show
protect
lethal
challeng
use
viru
smee
et
al
studi
use
pimodivir
oseltamivir
suggest
potenti
benefit
combin
therapi
trevejo
et
al
phase
clinic
studi
treatment
pimodivir
significantli
decreas
viral
load
day
versu
placebo
adult
patient
acut
uncompl
season
influenza
recent
pimodivir
receiv
fda
fast
track
design
due
potenti
address
unmet
medic
need
develop
influenza
infect
complic
phase
clinic
trial
aim
evalu
efficaci
safeti
pimodivir
combin
oseltamivir
adult
risk
develop
complic
current
recruit
patient
expect
conclud
octob
formerli
known
substitut
pyrazinecarboxamid
deriv
inhibitor
influenza
viru
polymeras
purin
nucleosid
analog
favipiravir
directli
inhibit
activ
rnadepend
rna
polymeras
furuta
et
al
broadspectrum
activ
influenza
subtyp
includ
resist
neuraminidas
inhibitor
furuta
et
al
preclin
studi
demonstr
broad
antivir
spectrum
compound
differ
human
avian
influenza
b
virus
includ
avian
influenza
virus
sidwel
et
al
watanab
et
al
shown
protect
reduct
viru
titer
infect
mice
furthermor
mice
treat
favipiravir
better
outcom
infect
compar
mice
treat
neuraminidas
inhibitor
watanab
et
al
combin
therapi
studi
found
drug
work
synergist
neuraminidas
inhibitor
improv
lung
viru
titer
bodi
weight
loss
surviv
mice
infect
pandem
influenza
viru
tarbet
et
al
avian
influenza
viru
smee
et
al
favipiravir
approv
japan
use
restrict
patient
infect
influenza
viru
resist
nai
event
pandem
toyama
chemic
co
ltd
condit
put
place
due
concern
teratogen
identifi
anim
experi
coupl
phase
clinic
trial
aim
determin
efficaci
safeti
favipiravir
treatment
uncompl
influenza
infect
adult
complet
result
publish
yet
new
phase
clinic
trial
studi
determin
pharmacokinet
favipiravir
patient
sever
influenza
report
activ
current
recruit
estim
studi
complet
date
march
promis
broadspectrum
antiinfluenza
antivir
also
broad
antivir
activ
sever
rna
virus
davidson
coupl
caveat
may
limit
use
antivir
compassion
use
case
emerg
reemerg
virus
treatment
avail
favipiravir
potenti
teratogen
embryotox
reason
condit
approv
japan
furuta
et
al
studi
sampl
obtain
clinic
trial
test
emerg
mutat
virus
obtain
pair
patient
day
initi
treatment
show
emerg
amino
acid
substitut
rna
polymeras
subunit
although
mutat
significantli
reduc
suscept
favipiravir
takashita
et
al
vitro
escal
studi
show
influenza
virus
adapt
low
concentr
compound
highlight
potenti
influenza
viru
strain
possibl
develop
resist
ormond
et
al
also
known
recombin
sialidas
compos
catalyt
domain
bacteri
sialidas
actinomyc
viscosu
epitheliumanchor
domain
human
protein
amphiregulin
malakhov
et
al
human
respiratori
tract
cell
surfac
sialic
acid
primari
receptor
bind
entri
influenza
virus
fludas
work
remov
sialic
receptor
airway
epithelium
therefor
prevent
viral
entri
cell
respiratori
epithelium
trianabaltz
et
al
preclin
vitro
studi
show
fludas
broadspectrum
antiinfluenza
antivir
potent
antivir
activ
human
avian
influenza
virus
cellular
toxic
trianabaltz
et
al
vivo
studi
show
mice
rescu
influenza
infect
treatment
fludas
includ
infect
highli
pathogen
virus
belser
et
al
marjuki
et
al
random
doubleblind
placebocontrol
phase
studi
conduct
determin
effect
dose
healthi
adult
particip
laboratoryconfirm
influenza
observ
treatment
fludas
significantli
reduc
viral
load
viral
shed
multipl
dose
addit
signific
advers
effect
observ
patient
receiv
treatment
moss
et
al
phase
clinic
trial
observ
longer
treatment
day
patient
develop
antibodi
compound
lead
reduc
efficaci
zenilman
et
al
nitazoxanid
ntz
origin
develop
licens
antiprotozo
drug
treatment
enter
caus
cryptosporidium
giardia
infect
nitazoxanid
thiazolid
compound
rapidli
deacetyl
blood
activ
metabol
form
tizoxanid
rossignol
addit
antiparasit
activ
compound
shown
activ
broad
rang
virus
includ
influenza
virus
belardo
et
al
tilmani
et
al
stachulski
et
al
mechan
action
influenza
viru
achiev
impair
traffick
viral
hemagglutinin
ha
endoplasm
reticulum
golgi
apparatu
block
ha
termin
glycosyl
lead
block
matur
ha
rossignol
et
al
preclin
studi
demonstr
antivir
activ
differ
strain
influenza
b
virus
vitro
includ
avian
influenza
virus
sleeman
et
al
publish
studi
antivir
efficaci
ntz
anim
model
although
extens
pharmacolog
test
perform
anim
koszalka
et
al
nitazoxanid
exampl
repurpos
drug
lot
studi
human
facilit
advanc
drug
treatment
influenza
viru
infect
rossignol
phase
clinic
trial
aim
determin
safeti
efficaci
ntz
treatment
acut
uncompl
influenza
establish
treatment
mg
twice
day
day
well
toler
associ
reduct
symptom
infecti
viral
load
haffizulla
et
al
phase
studi
evalu
efficaci
safeti
nitazoxanid
tablet
stachulski
et
al
treatment
uncompl
influenza
conclud
march
result
post
two
rsv
antivir
drug
approv
fda
treatment
prevent
seriou
respiratori
tract
infect
caus
rsv
aerosol
ribavirin
treatment
palivizumab
prophylaxi
guanosin
analog
ribavirin
broadspectrum
antivir
agent
activ
rsv
rna
virus
hepat
c
zika
virus
antonini
et
al
kim
et
al
zhurilo
et
al
benefici
effect
drug
inhibit
rsv
replic
demonstr
sever
studi
ribavirin
show
antivir
activ
rsv
reduc
rsv
lung
titer
infect
cotton
rat
bonavia
et
al
similarli
signific
clinic
benefit
observ
children
treat
aerosol
ribavirin
earli
infect
devincenzo
howev
clinic
applic
ribavirin
limit
nonspecif
antirsv
activ
risk
potenti
toxic
rel
high
cost
sun
et
al
palivizumab
human
monoclon
antibodi
found
strong
rsvneutral
capabl
rang
rsv
strain
palivizumab
epitop
structur
rsv
f
protein
well
character
schickli
et
al
drug
shown
effect
prevent
rsvrelat
hospit
children
frogel
et
al
although
efficaci
antivir
rsv
infect
proven
due
consider
cost
palivizumab
usag
limit
highrisk
popul
shahabi
et
al
includ
infant
young
children
center
diseas
control
prevent
aqueou
intraven
polyclon
human
immunoglobulin
g
igg
pool
sourc
plasma
screen
healthi
adult
donor
high
level
rsvneutral
antibodi
result
phase
studi
respect
demonstr
prepar
met
accept
pharmacokinet
safeti
criteria
achiev
foldchang
increas
titer
antirsv
neutral
antibodi
patient
wasserman
et
al
fulli
human
mab
produc
velocimmun
mice
bind
specif
f
protein
rsv
preclin
studi
cotton
rat
demonstr
effect
reduc
rsv
viral
replic
lung
gurnettband
et
al
although
result
two
clinic
trial
phase
healthi
adult
show
antibodi
well
toler
halflif
longer
typic
mab
low
immunogen
sivapalasingam
et
al
result
recent
phase
trial
preterm
infant
reveal
mab
meet
primari
endpoint
prevent
rsv
recombin
human
mab
engin
fc
region
longer
serum
halflif
design
prevent
lower
respiratori
tract
ill
lrti
caus
rsv
antibodi
bind
prefus
conform
f
protein
rsv
result
placebocontrol
studi
healthi
adult
healthi
preterm
infant
show
increas
mean
halflif
moreov
safeti
profil
similar
placebo
griffin
et
al
domachowsk
et
al
evalu
efficaci
mab
prevent
infect
clinic
studi
still
need
target
popul
infant
enter
first
rsv
season
first
nanobodi
develop
treatment
rsv
infect
trival
nanobodi
kda
bind
antigen
site
ii
rsv
f
protein
neutral
subtyp
rsv
vitro
neutral
effici
greater
palivizumab
detal
et
al
preclin
studi
cotton
rat
neonat
lamb
indic
highli
effect
reduc
nasal
lung
rsv
titer
hanton
et
al
detal
et
al
result
phase
clinic
studi
demonstr
inhal
inhibit
rsv
replic
reduc
viral
load
compar
placebo
current
clinic
trial
treat
infant
hospit
rsv
infect
van
heek
et
al
murin
mab
bind
central
conserv
region
rsv
g
protein
interfer
attach
process
block
g
protein
bind
johnson
et
al
rsvchalleng
mice
studi
show
earli
treatment
mab
reduc
pulmonari
inflamm
lung
viru
titer
hayn
et
al
clinic
studi
need
evalu
safeti
efficaci
antivir
human
motavizumab
recombin
human
mab
bind
linear
conform
epitop
ffl
rsv
f
glycoprotein
zhu
et
al
preclin
studi
cotton
rat
demonstr
mab
decreas
rsv
titer
time
lung
comparison
palivizumab
wu
et
al
phase
clinic
trial
show
motavizumab
well
toler
healthi
adult
prematur
infant
well
highrisk
children
chronic
lung
diseas
prematur
abarca
et
al
brien
et
al
result
recent
phase
clinic
trial
prevent
seriou
rsv
diseas
healthi
term
infant
indic
motavizumab
reduc
proport
infant
admit
hospit
rsv
brien
et
al
oral
bioavail
rsv
fusion
inhibitor
shown
prevent
rsv
entri
block
viruscel
fusion
process
samuel
et
al
preclin
studi
conduct
cotton
rat
effici
bioavail
penetr
drug
lung
tissu
observ
result
clinic
studi
healthi
volunt
experiment
infect
rsv
indic
oral
administr
result
reduct
viral
load
diseas
sever
mackman
et
al
clinic
trial
complet
differ
popul
includ
rsvinfect
hospit
patient
lung
transplant
recipi
hematopoiet
stem
cell
transplant
recipi
result
avail
yet
recent
publish
result
phase
trial
hospit
adult
rsv
show
signific
reduct
viral
load
improv
clinic
outcom
diseas
hanfeltgoad
et
al
clarifi
efficaci
drug
studi
requir
infant
children
fusion
inhibitor
shown
inhibit
rsv
entri
cell
vitro
report
preclin
studi
cotton
rat
demonstr
antirsv
activ
compound
effect
subtyp
rsv
kim
et
al
reformul
form
administ
powder
inhal
quick
deliveri
respiratori
tract
wyde
et
al
result
phase
clinic
trial
indic
safeti
desir
pharmacokinet
profil
drug
healthi
adult
kim
et
al
potent
rsvspecif
fusion
inhibitor
shown
act
effect
antirsv
vitro
anim
model
royman
et
al
ackermann
et
al
clinic
studi
healthi
adult
assess
antivir
efficaci
well
safeti
shown
reduc
rsv
viral
load
respiratori
infect
sever
caus
rsv
durat
diseas
israel
et
al
huntjen
et
al
studi
need
infant
children
prove
antivir
activ
antirsv
candid
novel
compound
develop
inhibit
rsv
replic
block
viral
entri
target
cell
placebocontrol
phase
clinic
trial
show
oral
administr
antivir
well
toler
among
healthi
volunt
meet
standard
safeti
profil
toovey
et
al
phase
clinic
trial
hospit
infant
infect
rsv
current
underway
small
substitut
benzimidazol
rsv
fusion
inhibitor
improv
deriv
compound
antivir
activ
rsv
b
long
tissu
retent
time
anim
model
creat
concern
stop
develop
wyde
et
al
bonfanti
et
al
contrast
lack
long
tissu
retent
maintain
high
antivir
activ
vitro
bonfanti
et
al
use
preclin
studi
cotton
rat
rouan
et
al
african
green
monkey
ispa
et
al
reveal
reduct
viral
load
dosedepend
manner
lung
inflamm
base
data
could
drug
candid
treatment
rsv
infect
howev
safeti
studi
clinic
evalu
still
need
small
molecul
submicromolar
rsv
activ
discov
chemic
optim
rsv
highthroughput
screen
hit
chapman
et
al
effect
rsv
b
replic
postentri
step
antivir
mechan
compound
relat
bind
rsv
n
protein
therefor
inhibit
rna
synthesi
infect
releas
viru
challa
et
al
phase
clinic
trial
stem
cell
transplant
patient
rsv
infect
show
follow
treatment
plasma
exposur
reach
effect
concentr
addit
patient
reduct
viral
titer
rsv
infect
symptom
marti
et
al
small
interf
rna
sirna
nucleotid
target
highli
conserv
region
rsv
nucleoprotein
gene
sirna
shown
effect
prophylaxi
treatment
model
result
preclin
studi
mice
indic
treatment
achiev
reduct
rsv
lung
titer
comparison
control
group
lu
et
al
intranas
administr
healthi
volunt
inocul
rsv
show
signific
reduct
rsv
infect
activ
drug
recipi
compar
placebo
recipi
group
devincenzo
et
al
phase
clinic
trial
conduct
lung
transplant
recipi
rsv
infect
good
safeti
profil
posit
benefit
sirna
observ
reduc
risk
bronchiol
obliteran
syndrom
gottlieb
et
al
evalu
antivir
natur
rsvinfect
children
infant
establish
nucleosid
rsv
polymeras
inhibitor
high
level
oral
bioavail
preclin
studi
african
green
monkey
infect
rsv
treat
oral
demonstr
effici
antivir
activ
deval
et
al
clinic
trial
healthi
adult
experiment
infect
rsv
reveal
shorter
rsv
rna
clearanc
time
treat
group
compar
placebo
recipi
reduct
rsv
viral
load
rang
nasal
wash
treat
individu
devincenzo
et
al
use
plasma
obtain
recov
patient
convalesc
plasma
shown
benefici
effect
outbreak
sar
influenza
viru
infect
altawfiq
et
al
studi
infect
indic
use
cp
reduc
viral
load
mortal
mairjenkin
et
al
wu
et
al
due
lack
clinic
data
demonstr
efficaci
merscov
infect
use
cp
consid
investig
treatment
world
health
organ
two
case
report
use
intraven
immunoglobulin
part
integr
treatment
intervent
therefor
benefici
effect
readili
quantifi
kapoor
et
al
arabi
et
al
preclin
studi
passiv
transfer
sera
merscov
immun
camel
infect
mice
reduc
weight
loss
lung
histopatholog
zhao
et
al
protocol
determin
safeti
effect
cp
therapi
patient
infect
merscov
recent
publish
arabi
et
al
studi
author
conclud
due
variat
level
merscovspecif
immunoglobulin
recov
patient
larg
screen
necessari
obtain
suffici
plasma
donor
clinic
studi
regist
base
find
sinc
withdrawn
use
cp
remain
potenti
therapeut
intervent
lack
evid
prove
safeti
efficaci
treat
infect
patient
limit
potenti
impact
mustafa
et
al
transchromosom
cattl
develop
produc
fulli
human
polyclon
igg
antibodi
follow
immun
matsushita
et
al
use
technolog
polyclon
sera
contain
antibodi
spike
protein
merscov
produc
demonstr
effect
neutral
viru
vitro
reduc
lung
viru
titer
infect
mice
luke
et
al
phase
random
clinic
trial
aim
evalu
safeti
toler
conduct
result
publish
show
polyclon
human
antibodi
safe
well
toler
patient
could
consid
therapeut
dose
beigel
et
al
use
velocimmun
mice
regeneron
produc
fulli
human
mab
bind
spike
protein
merscov
two
lead
mab
candid
regn
regn
character
vitro
vivo
pascal
et
al
vitro
mab
potent
neutral
merscov
vivo
studi
mous
model
infect
demonstr
treatment
infect
mice
caus
reduct
lung
viru
titer
histopatholog
pascal
et
al
phase
clinic
trial
evalu
safeti
toler
pharmacokinet
pk
immunogen
singl
ascend
dose
combin
mab
administ
iv
healthi
adult
volunt
current
underway
one
main
strategi
implement
clinic
treatment
merscov
use
broadli
act
antivir
although
support
therapi
continu
primari
approach
treatment
modjarrad
antivir
interferon
ribavirin
show
strong
inhibit
merscov
vitro
use
clinic
differ
degre
success
ribavirin
synthet
guanosin
nucleosid
interfer
synthesi
viral
mrna
best
effect
observ
use
combin
therapi
interferon
ifn
ribavirin
momattin
et
al
differ
type
interferon
includ
use
manag
patient
confirm
merscov
infect
mcintosh
studi
use
macaqu
anim
treat
ribavirin
stare
h
infect
merscov
falzarano
et
al
infect
anim
euthan
h
postinfect
peak
diseas
model
group
receiv
combin
treatment
develop
overt
clinic
sign
infect
reduc
level
proinflammatori
cytokin
reduct
lung
viru
titer
reduct
overal
lung
patholog
compar
group
macaqu
receiv
treatment
data
efficaci
combin
therapi
retrospect
studi
mo
fisher
mcintosh
studi
compar
infect
patient
receiv
combin
therapi
addit
support
therapi
observ
patient
significantli
better
surviv
day
postlaboratori
confirm
infect
compar
patient
receiv
support
therapi
omrani
shalhoub
case
studi
report
health
worker
infect
merscov
use
plu
ribavirin
associ
recoveri
well
benefici
prophylact
effect
spous
develop
mild
respiratori
ill
khalid
et
al
also
use
combin
therapi
treatment
merscov
infect
shalhoub
et
al
arabi
et
al
retrospect
studi
analyz
small
cohort
patient
laboratoryconfirm
infect
observ
treatment
combin
ribavirin
significantli
improv
surviv
shalhoub
et
al
differ
retrospect
studi
analysi
data
demonstr
administr
improv
surviv
treat
patient
howev
multivari
analysi
posit
effect
signific
al
ghamdi
et
al
result
vari
differ
retrospect
studi
part
due
presenc
comorbid
importantli
time
treatment
initi
altawfiq
memish
sinc
observ
window
opportun
narrow
effect
start
within
first
h
confirm
diagnosi
momattin
et
al
altawfiq
et
al
widagdo
et
al
case
studi
merscovinfect
patient
receiv
ribavirin
combin
lopinavirritonavir
human
immunodefici
viru
antivir
report
regimen
effect
treat
patient
kim
et
al
patient
male
differ
comorbid
start
treatment
day
post
admiss
achiev
viral
clearanc
day
initi
treatment
final
discharg
hospit
day
admiss
kim
et
al
recent
studi
combin
ribavirin
lopinavirritonavir
use
postexposur
prophylaxi
health
care
worker
expos
merscovinfect
patient
demonstr
reduct
risk
infect
park
et
al
preclin
studi
common
marmoset
infect
merscov
show
treatment
combin
lopinavirritonavir
improv
clinic
patholog
outcom
infect
anim
chan
et
al
phase
clinic
trial
determin
feasibl
efficaci
safeti
combin
therapi
lopinavirritonavir
treatment
merscovinfect
patient
initi
clinic
trial
expect
conclud
juli
howev
result
activ
report
review
summar
current
antivir
avail
treatment
influenza
rsv
along
potenti
new
therapi
respiratori
viru
infect
tabl
also
address
current
therapi
employ
broadspectrum
antivir
treatment
merscovinfect
patient
tabl
greater
advanc
achiev
field
influenza
antivir
current
three
group
drug
approv
treatment
influenza
includ
newli
approv
viral
polymeras
inhibitor
baloxavir
marboxil
one
approv
rsv
polyclon
palivizumab
although
effect
drug
limit
reduc
window
opportun
potenti
produc
drugresist
virus
high
cost
palivizumab
highlight
need
better
antivir
drug
treat
respiratori
infect
merscov
recent
emerg
zoonot
respiratori
infect
therefor
effect
antivir
approv
treatment
initi
approach
follow
exampl
antivir
therapi
use
recent
sar
outbreak
howev
describ
review
approach
use
broadspectrum
antivir
success
great
advanc
made
last
year
sever
antivir
current
develop
mani
reach
earli
stage
clinic
trial
excit
evolv
field
continu
produc
effect
antivir
highli
need
treatment
respiratori
viral
infect
global
public
health
concern
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
